Loading...

BCLI BRAINSTORM CELL THERAPEUTICS INC Delisting Actions 8-K Filing

BRNS

BCL

BRAINSTORM CELL THERAPEUTICS INC

(BCLI)

2024 8-K

Show Summary

Summary

Management Changes

Financial Statements

Bylaws Amendment

Financial Results

Warrant Agreement

Nasdaq Compliance Extension

Nasdaq Delisting Appeal

Nasdaq Delisting Notice

Financial Results

Nasdaq Compliance

Company Presentation

Stock Split Announcement

Shareholder Approvals

Financial Results

Announcement of Annual Meeting

Delisting Notice

Securities Purchase Agreement

FDA Alignment for NurOwn Ph...

Appointment of Dr. Hartoun ...

Management Changes

Compliance regained with Mi...

FDA Agreement for Phase 3b ...

Distribution Agreement Amen...

Financial Results Announcement

Annual Meeting of Stockholders

FDA Meeting for NurOwn in ALS

Delisting Notice

Delisting Notice

Costs Associated with Exit ...

Equity Offerings

Resignation and Appointment...

FDA Review of ALS Stem Cell...

Financial Results Announcement

FDA Advisory Committee Meet...

Annual Meeting of Stockholders

Amendment and Separation Ag...

External Links:

Brainstorm Cell Therapeutics Inc. has regained compliance with Nasdaq's minimum bid price requirement, allowing its common stock to continue trading on the Nasdaq Capital Market after a reverse stock split.

AI Assistant

BRAINSTORM CELL THERAPEUTICS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.